Percutaneous treatment of saphenous vein graft disease

Percutaneous treatment of saphenous vein graft disease: the ongoing challenge.

Although virtually all of the 400,000 coronary bypass surgeries performed in the U.S. each year use at least one arterial graft conduit (internal mammary or free radial), most still involve the placement of one or more saphenous vein grafts. These grafts immediately begin to develop intimal hyperplasia in response to surgical trauma, a loss of intrinsic vascular supply, and exposure of the thin...

Percutaneous Coronary Intervention of Saphenous Vein Graft.

BACKGROUND Percutaneous coronary intervention (PCI) of saphenous vein grafts (SVGs) has historically been associated with a high risk of adverse ischemic events, but there is a paucity of contemporary data on the second-generation drug-eluting stent use within SVG, and the relative importance of high platelet reactivity (HPR) in SVG PCI versus native lesion PCI is unknown. We studied ischemic a...

Saphenous vein graft percutaneous coronary intervention

In this issue of the Netherlands Heart Journal, IJsselmuiden et al. present a multicentre randomised control trial in which the STENTYS self-expanding bare metal stent (BMS) is compared with the STENTYS paclitaxel-eluting stent (PES) in saphenous vein grafts (SVGs). Primary endpoint of the trial was late lumen loss at six months follow-up, secondary endpoint was major adverse cardiac events (MA...

Tools & techniques: Percutaneous intervention of saphenous vein graft lesions.

© Europa Digital & Publishing 2013. All rights reserved. Background The percutaneous treatment of patients with obstructive atherosclerotic disease in coronary saphenous vein bypass grafts (SVG) remains a challenge in interventional cardiology. Patients undergoing SVG intervention are often older, and suffer significant comorbidities. Moreover, SVGs usually present a degenerated pattern of athe...

Saphenous Vein Graft Aneurysms